Article Text

PDF
Cancer stem cells in colorectal cancer: a review
  1. Matthew J Munro1,2,
  2. Susrutha K Wickremesekera1,3,
  3. Lifeng Peng2,
  4. Swee T Tan1,4,
  5. Tinte Itinteang1
  1. 1Gillies McIndoe Research Institute, Wellington, New Zealand
  2. 2School of Biological Sciences and Centre for Biodiscovery, Victoria University of Wellington, Wellington, New Zealand
  3. 3Department of General Surgery, Upper Gastrointestinal, Hepatobiliary & Pancreatic Section, Wellington Regional Hospital, Wellington, New Zealand
  4. 4Wellington Regional Plastic, Maxillofacial & Burns Unit, Hutt Hospital, Wellington, New Zealand
  1. Correspondence to Dr Swee T Tan, Gillies McIndoe Research Institute, Wellington 6242, New Zealand; swee.tan{at}gmri.org.nz

Abstract

Colorectal cancer (CRC) is the second most common cancer in women and the third most common in men. Adenocarcinoma accounts for 90% of CRC cases. There has been accumulating evidence in support of the cancer stem cell (CSC) concept of cancer which proposes that CSCs are central in the initiation of cancer. CSCs have been the focus of study in a range of cancers, including CRC. This has led to the identification and understanding of genes involved in the induction and maintenance of pluripotency of stem cells, and markers for CSCs, including those investigated specifically in CRC. Knowledge of the expression pattern of CSCs in CRC has been increasing in recent years, revealing a heterogeneous population of cells within CRC ranging from pluripotent to differentiated cells, with overlapping and sometimes unique combinations of markers. This review summarises current literature on the understanding of CSCs in CRC, including evidence of the presence of CSC subpopulations, and the stem cell markers currently used to identify and localise these CSC subpopulations. Future research into this field may lead to improved methods for early detection of CRC, novel therapy and monitoring of treatment for CRC and other cancer types.

  • colorectal cancer
  • cancer stem cells
  • stem cell markers
  • embryonic stem cells
View Full Text

Statistics from Altmetric.com

Footnotes

  • Handling editor Runjan Chetty

  • Contributors MJM drafted the manuscript. MJM, SKW, LP, STT and TI commented on and revised the manuscript.

  • Competing interests TI and STT are inventors of the PCT patent application (No. PCT/NZ2015/050108) Cancer Diagnosis and Therapy, and Cancer Therapeutic (US62/452479). The authors declare no other conflicts of interest.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.